Network identification

PURI

https://redirect.ema.europa.eu/resource/2221244

Network ID

2221244

Network name and Acronym

EU-ADR Alliance

ENCePP partner

No

Institutions that are part of this network

Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina
Bordeaux PharmacoEpi, University of Bordeaux
Health Search, Italian College of General Practicioners

Studies conducted by the network

EUROPEAN NON-INTERVENTIONAL POST AUTHORIZATION SAFETY STUDY RELATED TO SERIOUS INFECTIONS FOR ROMOSOZUMAB BY THE EU ADR ALLIANCE
EUROPEAN NON-INTERVENTIONAL POST-AUTHORIZATION SAFETY STUDY RELATED TO ADHERENCE TO THE RISK MINIMIZATION MEASURES FOR ROMOSOZUMAB BY THE EU-ADR ALLIANCE
European non-interventional post-authorization safety study related to serious cardiovascular events of myocardial infarction and stroke, and all-cause mortality for romosozumab by the EU-ADR Alliance
European Program of Post-Authorization Safety Studies for Protelos®/Osseor® through EU-ADR Alliance
Monitoring the effectiveness of risk minimisation in patients treated with pioglitazone-containing products
Multinational database cohort study to assess RMP specified safety outcomes in association with indacaterol/glycopyrronium bromide in Europe
Multinational, multi-database cohort study to assess adverse cardiovascular and cerebrovascular outcomes and mortality in association with inhaled NVA237 in Europe (NVA237 PASS)
Multinational, multi-database drug utilization study of indacaterol/glycopyrronium bromide in Europe
Multinational, multi-database drug utilization study of inhaled NVA237 in Europe (NVA237 DUS)
Patterns and Determinants of Use of Oral Contraceptives in the European Union (Use of OC in the EU)
Risk of cardiac valve disorders associated with the use of biphosphonates (Cardiac valve disorders and biphosphonate use)
VALIDATION STUDY PROTOCOL (OP0007) FOR THE EUROPEAN NON-INTERVENTIONAL POST- AUTHORIZATION SAFETY STUDY RELATED TO SERIOUS CARDIOVASCULAR EVENTS OF MYOCARDIAL INFARCTION AND STROKE AND ALL-CAUSE MORTALITY FOR ROMOSOZUMAB BY THE EU-ADR ALLIANCE (OP0004) AND EUROPEAN NON-INTERVENTIONAL POST-AUTHORIZATION SAFETY STUDY RELATED TO SERIOUS INFECTIONS FOR ROMOSOZUMAB BY THE EU-ADR ALLIANCE (OP0006)